Is Cosentyx (secukinumab) a biosimilar of Cyltezo (adalimumab)?
No. Cosentyx is not a biosimilar of Cyltezo.
Cosentyx (secukinumab) and Cyltezo (adalimumab-adbm) target different biologic drugs. Cosentyx is an anti–IL-17A antibody, while Cyltezo is an anti–TNF (adalimumab) product. Because they are based on different reference biologics and have different targets, Cosentyx cannot be a biosimilar to Cyltezo.
What are Cyltezo and Cosentyx approved for, and does that affect whether one is a biosimilar?
They can be used for overlapping immune-mediated conditions, which can make the drugs seem interchangeable, but overlap in treating similar diseases does not make one a biosimilar of the other. Biosimilarity is based on a specific reference product and requires an approved biosimilar relationship to that reference, not just the same disease use.
Which drug is the biosimilar relationship tied to?
A biosimilar is approved as a biosimilar to a specific reference biologic. Cyltezo is an adalimumab biosimilar product (adalimumab-adbm). Cosentyx is secukinumab, a different biologic class and molecule from adalimumab, so it has no biosimilar relationship to Cyltezo.
Where to check biosimilar vs reference vs product name
For up-to-date product detail, DrugPatentWatch.com tracks biologics and related exclusivity/patent information, which can help confirm what product a biosimilar is tied to. See DrugPatentWatch.com here: https://www.drugpatentwatch.com/